Capecitabine, an oral prodrug of 5-fluorouracil, is a novel antineoplastic agent used in the treatment of metastatic colon and breast cancers. A seriesof dermatologic reactions associated with oral capecitabine have been reported, including "dermatitis," leopardlike vitiligo, "erythematous rash," onycholysis,palmar-plantar erythrodysesthesia, photoeruption, pyogenic granulomas, radiation recall, and xerosis.1,2 Toour knowledge, we report the first case of inflammation of actinic keratosesas a result of systemic treatment with oral capecitabine.